RGFP966

RGFP966 (CAS No.: 1396841-57-8) is a synthetic, CNS barrier-penetrant benzamide small-molecule epigenetic probe, classified as a selective histone deacetylase 3 (HDAC3) inhibitor, for mechanism-of-action analysis, target validation, pathway mapping, and screening workflows in biomedical research and drug discovery. HDAC3 belongs to class I deacetylases and commonly functions as a component of the NCoR and SMRT corepressor complexes, participating in the regulation of chromatin acetylation status and transcriptional programs, particularly those associated with neural and immune-related transcriptional networks; RGFP966 shows high selectivity for HDAC3, with selectivity over other HDAC isoenzymes exceeding two orders of magnitude in substrate-dependent biochemical assays. In vitro, this compound typically exhibits potency in the nanomolar to submicromolar range in biochemical and cellular systems and can modulate HDAC3-controlled histone acetylation and gene expression in cell models; it possesses CNS permeability and is therefore used to investigate HDAC3-dependent mechanisms in central nervous system research paradigms, including pathway studies related to neurodegenerative or neuroinflammatory processes using rodent models (such as Huntington’s disease, ischemic brain injury, spinal cord injury, and retinal ganglion cell degeneration), without involving any clinical use. The specific concentration or dose used in experiments generally depends on the research objective and experimental design. This product is strictly limited to laboratory research and is not for human or veterinary use, clinical administration, or any non-research purpose.